Overcoming the COVID-19 Pandemic in Indonesia: A Science, technology, and innovation (STI) policy perspective

Scientific abstract: R&D serves as one of the imperative aspects in handling the COVID-19 pandemic. Since the Indonesian government has declared the COVID-19 pandemic as a national disaster, a number of accelerated regulations were stipulated, engaging research and innovation acknowledged as Science, technology, and innovation (STI) Policy. The results of the regulation mapping in Indonesia during 2020-2021 include the 9 regulations (categorized as STI Policy and dominated by institutional settings of 44.4%, operational mechanisms of 33.3%, and legal devices of 22.3%) as an attempt to address the COVID-19 pandemic. Hence, it is expected that the implementation of STI Policy plays a role in generating the 50 innovation products through the COVID-19 research and innovation consortium. Public interest abstract: The COVID-19 pandemic has been declared as a national disaster in Indonesia. There are nine regulations in the field of Science, technology, and innovation (STI) Policy set by the Indonesian govern-ment until July 2021, which regulate institutions, by institutionalizing the implementation of research and innovation in the health sector. The institution is acknowledged as the COVID-19 Research Consortium, con-sisting of government R&D institutions, universities, industrial R&D institutions, professional associations, regulators, industry, and 50 research and innovation products which have been launched by this consortium.